# BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

> **NCT00098254** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** BAY 43-9006 (Sorafenib)

## Key facts

- **NCT ID:** NCT00098254
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2009-11
- **Final completion:** 2011-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2012-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098254, "BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00098254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*